UB-312 in Patients With Synucleinopathies

Summary

This is a Phase 1b study to determine the safety, tolerability, and immunogenicity of UB-312 in participants with multiple system atrophy (MSA), and in participants with Parkinson's disease (PD). UB-312 is a UBITh®-enhanced synthetic peptide-based vaccine and may provide an active immunotherapy option for treating synucleinopathies including the most prevalent form, PD; and the most rapidly progressive form, MSA.

Timeline

Start

2023-05-31

Primary completion

2025-02-11

Completion

2025-02-11

Drugs

Indications